Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Moreover, CLSD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises ...
Clearside Biomedical Inc (CLSD) stock saw a decline, ending the day at $1.23 which represents a decrease of $-0.12 or -8.89% from the prior close of $1.35. The stock opened at $1.38 and touched a low ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Fintel reports that on August 21, 2024, Chardan Capital initiated coverage of Clearside Biomedical (NasdaqGM:CLSD) with a Buy recommendation. As of August 6, 2024, the average one-year price ...